Article
Gastroenterology & Hepatology
Francesca Garuti, Andrea Neri, Francesca Avanzato, Annagiulia Gramenzi, Davide Rampoldi, Paola Rucci, Fabio Farinati, Edoardo G. Giannini, Fabio Piscaglia, Gian Ludovico Rapaccini, Maria Di Marco, Eugenio Caturelli, Marco Zoli, Rodolfo Sacco, Giuseppe Cabibbo, Fabio Marra, Andrea Mega, Filomena Morisco, Antonio Gasbarrini, Gianluca Svegliati-Baroni, Francesco G. Foschi, Gabriele Missale, Alberto Masotto, Gerardo Nardone, Giovanni Raimondo, Francesco Azzaroli, Gianpaolo Vidili, Maurizia R. Brunetto, Franco Trevisani
Summary: In Italy, over the last 15 years, there has been a gradual increase in age of HCC patients, a rise in non-viral cases, and improvements in clinical management. Different treatment methods have shown positive outcomes, leading to an overall increase in survival rates.
LIVER INTERNATIONAL
(2021)
Review
Biochemistry & Molecular Biology
Francesco Paolo Russo, Alberto Zanetto, Elisa Pinto, Sara Battistella, Barbara Penzo, Patrizia Burra, Fabio Farinati
Summary: Hepatocellular carcinoma (HCC) is a major cause of cancer-related death, with chronic viral hepatitis being a significant contributing factor. The pathophysiology of viral-related HCC involves liver inflammation, oxidative stress, and deregulation of cell signaling pathways. Regular ultrasound surveillance is recommended for patients with cirrhosis and high-risk individuals with chronic HBV infection. Antiviral therapy reduces the risks of HCC development and recurrence. Various scoring systems have been developed to predict the risk of HCC development in patients with chronic hepatitis B.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Multidisciplinary
Yaoru Huang, Po-Yung Chen, Tzu-Yen Cheng, Jeng-Fong Chiou
Summary: This study investigated the outcomes of reirradiation for recurrent HCC and found that better local control could prolong survival. The results suggest that reirradiation may be a viable treatment option for recurrent HCC.
APPLIED SCIENCES-BASEL
(2021)
Article
Oncology
Lei Zhang, JinFeng Wu, QiuMei Wu, XiangJuan Zhang, ShuaiCai Lin, WanLi Ran, Li Zhu, ChengYan Tang, Xing Wang
Summary: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death. The mechanisms behind male propensity in HCC incidence, prognosis, and treatment responses are complex and inconclusive. This review integrates current knowledge on how hormones regulate HCC development in a sexually dimorphic manner. Understanding the role of sex hormones in HCC may lead to personalized therapeutic strategies in high-risk populations.
Article
Oncology
Guoxin Hou, Zhimin Lu, Jialu Jiang, Xinmei Yang
Summary: By utilizing bioinformatic methods and experimental analysis, this study thoroughly investigated the clinical significance and biological functions of ribosomal protein L32 (RPL32) in hepatocellular carcinoma (HCC). The results showed that RPL32 was highly expressed in HCC samples and correlated with unfavorable outcomes. RPL32 was found to promote HCC cell proliferation, migration, and invasion.
Article
Oncology
Yu-Yun Shao, Ann-Lii Cheng, Chih-Hung Hsu
Summary: Hypothyroidism is common but often underdiagnosed in patients with advanced hepatocellular carcinoma. Both overt and subclinical hypothyroidism are associated with poorer prognosis in advanced HCC patients. Regular thyroid function checks before initiating systemic therapy for advanced HCC patients are crucial based on the findings of this study.
Article
Immunology
Tzu-Rong Peng, Chao-Chuan Wu, Sou-Yi Chang, Yen-Chih Chen, Ta-Wei Wu, Ching-Sheng Hsu
Summary: This study investigated the therapeutic efficacy of nivolumab plus sorafenib therapy in patients with unresectable HCC. The findings showed that the combination therapy resulted in better overall survival outcomes compared to sorafenib alone.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Surgery
Hikaru Hayashi, Akira Shimizu, Hiroaki Motoyama, Koji Kubota, Tsuyoshi Notake, Hitoshi Masuo, Takahiro Yoshizawa, Kiyotaka Hosoda, Hiroki Sakai, Koya Yasukawa, Yuji Soejima
Summary: This retrospective study shows that hepatectomy is safe and effective for octogenarians with hepatocellular carcinoma (HCC), with similar postoperative outcomes compared to younger patients.
ASIAN JOURNAL OF SURGERY
(2023)
Article
Oncology
Zhancheng Qiu, Weili Qi, Youwei Wu, Lingling Li, Chuan Li
Summary: This study examines the impact of public insurance status on the survival outcomes of HCC patients after liver resection in China. The results show that underinsured HCC patients have worse survival outcomes after liver resection. This may be due to the limited access to care for underinsured patients, but further exploration is needed for conclusive evidence.
Article
Medicine, General & Internal
Indah Jamtani, Kwang-Woong Lee, Yunhee Choi, YoungRok Choi, Jeong-Moo Lee, Eui-Soo Han, Kwangpyo Hong, Gyu-Seong Choi, Jong Man Kim, Nam-Joon Yi, Suk Kyun Hong, Jeik Byun, Su Young Hong, Sanggyeun Suh, Jae-Won Joh, Kyung-Suk Suh
Summary: This study aimed to develop a tailored prediction model of HCC-specific survival after transplantation, validated internally and externally. By combining multiple risk factors, the model showed good accuracy in predicting HCC-specific survival tailored for patients undergoing transplantation. The calculated SALT predictor provided accurate information on expected survival rates based on risk scores and specific characteristics.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Cheng Zhang, Shi Feng, Zhenhua Tu, Jingqi Sun, Tao Rui, Xueyou Zhang, Haitao Huang, Qi Ling, Shusen Zheng
Summary: Sarcomatoid HCC patients have larger tumors, higher differentiation grade, lower tumor-free and overall survival rates, with the sarcomatoid type being an independent risk factor for patient death. Integrating the sarcomatoid subtype into AJCC staging could improve predicting patient survival. The cancer genome analysis revealed a high mutation rate in cell cycle genes, particularly CDKN2A, in sarcomatoid HCC, suggesting CDK4/6 inhibitors as potential therapeutic targets.
Article
Oncology
Abhilasha Nair, Kelie Reece, Martha B. Donoghue, Weishi (Vivian) Yuan, Lisa Rodriguez, Patricia Keegan, Richard Pazdur
Summary: The FDA approved lenvatinib for first-line treatment of unresectable hepatocellular carcinoma based on the REFLECT trial, which showed noninferiority to sorafenib in terms of overall survival and statistically significant improvements in progression-free survival. Lenvatinib-treated patients had similar survival, more responses, and longer time to progression compared to those receiving sorafenib, but experienced more serious side effects. Lenvatinib is an effective option for previously untreated HCC patients.
Article
Radiology, Nuclear Medicine & Medical Imaging
Bang-Bin Chen, Po-Chin Liang, Tiffany Ting-Fang Shih, Tsung-Hao Liu, Ying-Chun Shen, Li-Chun Lu, Zhong-Zhe Lin, Chiun Hsu, Chih-Hung Hsu, Ann-Lii Cheng, Yu-Yun Shao
Summary: Sarcopenia and myosteatosis are independent prognostic factors in patients who received immunotherapy for advanced HCC.
EUROPEAN RADIOLOGY
(2023)
Article
Oncology
Chihao Zhang, Jiayun Lin, Xiaochun Ni, Hongjie Li, Lei Zheng, Zhifeng Zhao, Xiaoliang Qi, Haizhong Huo, Xiaolou Lou, Qiang Fan, Meng Luo
Summary: The study found a negative association between high OPG levels and survival rates in HCC patients, indicating OPG as a potential prognostic predictor for those undergoing radical resection. This association was further confirmed in specific subgroups.
FRONTIERS IN ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Jianping Wang, Peipei Cong, Zhipeng Jin, Lingli Liu, Dongxu Sun, Wenjing Zhu, Guangjun Shi
Summary: SUMOylation has a significant role in the progression of malignancies. This study aims to construct a signature for hepatocellular carcinoma (HCC) using SUMOylation-related genes (SRGs). Differentially expressed SRGs were identified through RNA sequencing and used to build a signature using Univariate Cox regression and LASSO analysis. The accuracy of the model was validated using ICGC and GEO datasets, and the risk score was found to be associated with cancer-related pathways.
SCIENTIFIC REPORTS
(2023)
Article
Gastroenterology & Hepatology
Alessandro Vitale, Gianluca Svegliati-Baroni, Alessio Ortolani, Monica Cucco, Giulio Dalla Riva, Edoardo G. Giannini, Fabio Piscaglia, Gianludovico Rapaccini, Mariella Di Marco, Eugenio Caturelli, Marco Zoli, Rodolfo Sacco, Giuseppe Cabibbo, Fabio Marra, Andrea Mega, Filomena Morisco, Antonio Gasbarrini, Francesco Giuseppe Foschi, Gabriele Missale, Alberto Masotto, Gerardo Nardone, Giovanni Raimondo, Francesco Azzaroli, Gianpaolo Vidili, Filippo Oliveri, Filippo Pelizzaro, Rafael Ramirez Morales, Umberto Cillo, Franco Trevisani, Luca Miele, Giulio Marchesini, Fabio Farinati
Summary: This study compared patients with MAFLD and non-MAFLD who had hepatocellular carcinoma (HCC) in Italy. It found that the proportion of MAFLD in HCC patients was increasing over time and is expected to surpass non-MAFLD in the future. Despite a later cancer stage at diagnosis, MAFLD HCC patients had a lower risk of HCC-related death, suggesting reduced cancer aggressiveness.
Article
Medicine, General & Internal
Quirino Lai, Nicoletta De Matthaeis, Michele Finotti, Giovanni Galati, Giuseppe Marrone, Fabio Melandro, Filomena Morisco, Daniele Nicolini, Riccardo Pravisani, Edoardo G. Giannini
Summary: This study evaluates the impact of antiplatelet therapy on the incidence and mortality of hepatocellular carcinoma. The results suggest that antiplatelet therapy is associated with a reduced risk of HCC incidence and post-treatment mortality.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2023)
Review
Gastroenterology & Hepatology
Stefano Kayali, Andrea Pasta, Maria Corina Plaz Torres, Ariel Jaffe, Mario Strazzabosco, Simona Marenco, Edoardo G. Giannini
Summary: This systematic review with pooled analysis assessed the safety and efficacy of immune checkpoint inhibitor (ICI) therapy in liver transplant recipients. The results showed that ICI treatment in these patients is associated with a risk of graft rejection and mortality, but some patients had disease control and longer overall survival. More prospective studies are needed to provide accurate data on the safety and efficacy of ICI treatment in this population.
LIVER INTERNATIONAL
(2023)
Review
Biochemistry & Molecular Biology
Nicolo Brandi, Daniele Spinelli, Alessandro Granito, Francesco Tovoli, Fabio Piscaglia, Rita Golfieri, Matteo Renzulli
Summary: The liver is a secondary target of COVID-19, which can cause complications in patients with existing liver disease and affect the management of liver disease patients. Liver imaging and telemedicine can be useful tools for identifying complications and overcoming challenges caused by the pandemic.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Neurosciences
Mattia Trunfio, Laura Di Girolamo, Laura Ponzetta, Marco Russo, Elisa Burdino, Daniele Imperiale, Cristiana Atzori, Giovanni Di Perri, Andrea Calcagno
Summary: HSV-1 chronic infection, but not HSV-2 and VZV, is independently associated with neurological abnormalities such as blood-brain barrier impairment, abnormal levels of tau and phosphorylated tau in cerebrospinal fluid, and decreased concentrations of beta amyloid fragment 1-42.
JOURNAL OF NEUROVIROLOGY
(2023)
Review
Gastroenterology & Hepatology
Andrea Pasta, Francesco Calabrese, Sara Labanca, Simona Marenco, Giulia Pieri, Maria Corina Plaz Torres, Nicolas M. Intagliata, Stephen H. Caldwell, Edoardo G. Giannini
Summary: This study aimed to assess the safety and efficacy of venous thromboembolism (VTE) prophylaxis in patients with cirrhosis. The results suggested that the current evidence is insufficient to advise for or against the use of VTE prophylaxis, mainly due to lack of quality and homogeneity of available data. However, the prophylaxis does not appear to be associated with a significant bleeding risk.
LIVER INTERNATIONAL
(2023)
Letter
Gastroenterology & Hepatology
Edoardo G. Giannini, Giacomo Borgonovo, Simona Marenco, Manuela Cesaretti
LIVER TRANSPLANTATION
(2023)
Article
Clinical Neurology
Aron Emmi, Michele Sandre, Francesco Paolo Russo, Giulia Tombesi, Federica Garri, Marta Campagnolo, Miryam Carecchio, Roberta Biundo, Gaya Spolverato, Veronica Macchi, Edoardo Savarino, Fabio Farinati, Piero Parchi, Andrea Porzionato, Luigi Bubacco, Raffaele De Caro, Gabor G. Kovacs, Angelo Antonini
Summary: This study revealed the presence of neuronal dysfunction and reactive gliosis in the duodenum of patients with Parkinson's disease, suggesting that the enteric nervous system is involved in the pathophysiology of the disease.
MOVEMENT DISORDERS
(2023)
Article
Infectious Diseases
Bianca Maria Longo, Francesco Venuti, Alberto Gaviraghi, Tommaso Lupia, Fabio Antonino Ranzani, Andrea Pepe, Laura Ponzetta, Davide Vita, Tiziano Allice, Vanesa Gregorc, Pio Manlio Mirko Frascione, Francesco Giuseppe De Rosa, Andrea Calcagno, Stefano Bonora
Summary: This study retrospectively included 15 immunosuppressed patients to investigate treatment strategies for persistent COVID-19. The results showed that sequential or combination regimens of antivirals and monoclonal antibodies were highly effective and safe in immunosuppressed patients.
Article
Biochemistry & Molecular Biology
Elisa Bernasconi, Matteo Biagi, Stefania Di Agostino, Carmela Cursaro, Cristina Felicani, Enrico Ronconi, Elena Franchi, Arianna Carmen Costanzo, Filippo Gabrielli, Alessia Cavicchioli, Giuseppe Ienopoli, Paolo Marenghi, Alessandra Bartoli, Beatrice Serra, Davide Scalabrini, Pamela Sighinolfi, Pietro Andreone
Summary: This study described a case series of patients who developed acute hepatitis following SARS-CoV-2 vaccination or infection, and speculated a possible genetic susceptibility in the pathogenesis.
Article
Gastroenterology & Hepatology
Alessandra Bartoli, Carmela Cursaro, Hajrie Seferi, Pietro Andreone
Summary: This review focuses on COVID-19 secondary sclerosing cholangiopathy (SSC) and its pathogenesis, with an emphasis on clinical, imaging, and histological findings. The most likely causes of the disease are direct viral cytopathic action and COVID-19-related coagulopathy. Ketamine may be a cofactor but cannot be definitively linked as the main determinant cause of cholangiopathy. Further study is needed due to the severe prognosis of the disease.
HEPATIC MEDICINE-EVIDENCE AND RESEARCH
(2023)
Review
Medicine, General & Internal
Elisa Pinto, Filippo Pelizzaro, Fabio Farinati, Francesco Paolo Russo
Summary: Hepatocellular carcinoma (HCC) is a common liver malignancy, and angiogenesis plays a crucial role in its development and progression. Deregulated angiogenic pathways have been identified as therapeutic targets in HCC. Locoregional and systemic treatments aim to disrupt tumor blood supply, but this may induce neoangiogenesis and tumor recurrence. Currently available tyrosine kinase inhibitors and monoclonal antibodies primarily target angiogenic pathways for HCC treatment.
MEDICINA-LITHUANIA
(2023)
Letter
Medicine, General & Internal
Edoardo G. Giannini, Tommaso Testa, Federica Grillo, Luca Mastracci, Serena Arrigo, Piero Cai, Sabrina Paolino, Martina Burlando, Livia Pisciotta, Elena Formisano, Giuseppe Cittadini, Francesco Copello, Sabrina Tuo, Giorgia Bodini
Summary: The establishment of an interdisciplinary IBD center is associated with improved healthcare utilization, including a decrease in hospitalizations per patient/year, a decrease in length of hospitalization, and an increase in patients on biologics.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2023)
Article
Clinical Neurology
Aron Emmi, Michele Sandre, Francesco Paolo Russo, Giulia Tombesi, Federica Garri, Marta Campagnolo, Miryam Carecchio, Roberta Biundo, Gaya Spolverato, Veronica Macchi, Edoardo Savarino, Fabio Farinati, Piero Parchi, Andrea Porzionato, Luigi Bubacco, Raffaele De Caro, Gabor G. Kovacs, Angelo Antonini
Summary: This study investigated the alterations of alpha-synuclein and glial responses in duodenum biopsies of Parkinson's disease (PD) patients. The findings provide evidence of synuclein pathology and gliosis in the duodenum of PD patients, including early cases, suggesting the important role of the gut in PD pathogenesis.
MOVEMENT DISORDERS
(2023)